Prime award
WESTAT, INC. · Department of Health and Human Services
PHASE I/II DOSE-FINDING, SAFETY, AND TOLERABILITY STUDY OF DAILY RIFAPENTINE (RPT) COMBINED WITH ISONIAZID (INH) (1HP) FOR TUBERCULOSIS PREVENTION IN CHILDREN TWO TO LESS THAN 13 YEARS OF AGE WITH AND WITHOUT HIV
Current value$2.22M
Obligated to date$0
Months remaining8
Sign in to mark this as watching, pursuing, or passed — and to be told when its end date changes.
Recompete signal
This award ends in 8 months.
Award record
| Field | Value |
|---|---|
| Recipient | WESTAT, INC. |
| Awarding agency | Department of Health and Human Services |
| NAICS | 541715 |
| PSC | AN11 |
| Place of performance | MD |
| Period | → May 31, 2027 |
| Competition | A |
| Vehicle | Standalone |
Data & sources
Record as published by USAspending.gov, vintage FY2021–FY2025 full archives · USAspending.gov, retrieved Aug 6, 2026. Values change as modifications are reported; obligations may be negative when work is de-obligated.